Skip to content

Company · founded 2016

Fulcrum Therapeutics (United States)

Cambridge, United States · fulcrumtx.com

Manage this page

Citations, last 5 years: 214
Works, last 5 years: 67
h-index: 43
Scientists listed: 5
Grants since 2016: 9

Grants received

2022–2024 · research · R42

Commercialization of Selective Dyrk1a Inhibitors for Down Syndrome

Travis Dunckley · Fulcrum Therapeutics (United States) · funded by National Institutes of Health

$498.6kDown syndrome and intellectual disability research

2022–2026 · research · R44

Commercialization of Selective Dyrk1a Inhibitors for Down Syndrome

Travis Dunckley · Fulcrum Therapeutics (United States) · funded by National Institutes of Health

$1.5MDown syndrome and intellectual disability research

2022–2027 · research · R44

Commercialization of Selective Dyrk1a Inhibitors for Down Syndrome

Travis Dunckley · Fulcrum Therapeutics (United States) · funded by National Institutes of Health

$1.4M

2021–2023 · research · R43

Chemokine-receptor profiling for painful diabetic neuropathy in biological samples from human clinical trials

Thomas P Richardson · Fulcrum Therapeutics (United States) · funded by National Institutes of Health

$700.1kPain Mechanisms and Treatments

2021–2027 · research · R44

Laboratory Developed Test (LDT) to Support Clinical Evaluation of a Drug for Painful Diabetic Neuropathy

Thomas P Richardson · Fulcrum Therapeutics (United States) · funded by National Institutes of Health

$1.5M

2019–2022 · research · R44

A Novel Approach to Restore Epithelial Barrier Homeostasis to Treat Inflammatory Bowel Disease

W Vallen Graham · Fulcrum Therapeutics (United States) · funded by National Institutes of Health

$795k

2019–2021 · research · R43

A Novel Approach to Restore Epithelial Barrier Homeostasis to Treat Inflammatory Bowel Disease

W Vallen Graham · Fulcrum Therapeutics (United States) · funded by National Institutes of Health

$224.3k

2018–2020 · research · R43

Chemokine-receptor expression profiling in biological samples from human clinical trials

Thomas P Richardson · Fulcrum Therapeutics (United States) · funded by National Institutes of Health

$225kPain Mechanisms and Treatments

2018–2019 · research · R43

Chemokine-receptor expression profiling in biological samples from human clinical trials

Thomas P Richardson · Fulcrum Therapeutics (United States) · funded by National Institutes of Health

$55k